^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    Arbele

    i
    Other names: Arbele
    Evidence

    News

    over1year
    Arbele Announces Strategic Collaborations on AI Precision Oncology and Manufacturing to Advance CDH17-Targeted Immunotherapeutics (PRNewswire)
    "Arbele...is pleased to announce strategic collaborations in precision oncology using artificial intelligence (AI) to advance targeted immunotherapeutics of bispecific T-cell engagers (TCEs) and antibody-drug conjugates (ADCs). These partnerships, aimed at advancing the quantification and prognostic prediction of CDH17 expression in tumor tissue and the surrounding tumor immune microenvironment, are expected to accelerate the development of precise companion diagnostics and effective clinical trials for the treatment of advanced cancer patients."
    Commercial • Licensing / partnership
    over1year
    BioAI Announces Strategic Partnership with Arbele Bio to advance Predictive AI-Models in Oncology Clinical Trials (PRNewswire)
    "BioAI...has announced a strategic partnership with Arbele, a biopharmaceutical company dedicated to developing novel immunotherapeutic platforms for gastrointestinal cancers. The collaboration aims to leverage BioAI's PredictX platform to develop AI-based models using Arbele's clinical trial data, with a focus on colorectal cancer (CRC) biomarker screening. The goal is to create a companion diagnostic test for Arbele's drug assets, enhancing patient selection through advanced AI technology....The initial phase of the partnership will focus on developing a prototype machine learning classifier model for quantifying CDH17 expression patterns in CRC samples, using a combination of H&E (hematoxylin and eosin) and IHC (immunohistochemistry) stained images."
    Licensing / partnership